{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:39:33Z","timestamp":1790746773299,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178032","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:54:04Z","timestamp":1754430844000},"page":"178032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A first-in-class JAK\/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study"],"prefix":"10.1016","volume":"1005","author":[{"given":"Minghua","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duoer","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanli","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunkang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.178032_bib1","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of Ruxolitinib in patients with myelofibrosis, including those with low PLT counts","volume":"189","author":"Al-Ali","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2025.178032_bib2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib4","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing Ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib5","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2016.377","article-title":"Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia","volume":"31","author":"Fisher","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2025.178032_bib7","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, PLT count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib8","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib9","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and Personalized Prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178032_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/bjh.19257","article-title":"Evidence creation for myelofibrosis: Challenges and opportunities","volume":"204","author":"Gupta","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejphar.2025.178032_bib11","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178032_bib12","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with Ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejphar.2025.178032_bib13","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with Ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejphar.2025.178032_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after Ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ejphar.2025.178032_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.25777","article-title":"Fedratinib in patients with myelofibrosis previously treated with Ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for Ruxolitinib failure","volume":"95","author":"Harrison","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.ejphar.2025.178032_bib16","doi-asserted-by":"crossref","first-page":"e729","DOI":"10.1016\/S2352-3026(24)00212-6","article-title":"Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with Ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"11","author":"Harrison","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejphar.2025.178032_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/13543784.2023.2269078","article-title":"Novel Janus-kinase (JAK) inhibitors in myelofibrosis","volume":"32","author":"Ipek","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejphar.2025.178032_bib38","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2018.03.024","article-title":"Dual targeting of oncogenic activation and inflammatory signaling increases therapeutic efficacy in myeloproliferative neoplasms","volume":"33","author":"Kleppe","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2025.178032_bib18","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178032_bib19","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-024-44703-7","article-title":"ROCK1\/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease","volume":"15","author":"Maas-Bauer","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.178032_bib20","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including Ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib39","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: Pelabresib in combination with Ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1089\/jpm.2021.0599","article-title":"Eastern cooperative oncology group performance status #434","volume":"25","author":"Mischel","year":"2022","journal-title":"J. Palliat. Med."},{"key":"10.1016\/j.ejphar.2025.178032_bib23","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after Ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2025.178032_bib24","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.33541","article-title":"Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: frequency, therapeutic effects, and impact on outcome","volume":"127","author":"Palandri","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2025.178032_bib25","doi-asserted-by":"crossref","first-page":"S596","DOI":"10.1016\/j.annonc.2024.08.850","article-title":"Mini oral 799: The primary results from a randomized double-blind phase II study of rovadicitinib versus hydroxyurea in patients with myelofibrosis","volume":"35","author":"Pan","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib27","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","article-title":"The role of JAK2 inhibitors in MPNs 7 years after approval","volume":"131","author":"Passamonti","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.3324\/haematol.2020.262691","article-title":"Persistence of myelofibrosis treated with Ruxolitinib: biology and clinical implications","volume":"106","author":"Ross","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2025.178032_bib29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib30","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of Ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.178032_bib32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with Ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ejphar.2025.178032_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with Ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejphar.2025.178032_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.178032_bib35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/01.HS9.0000846884.97738.71","article-title":"P1004: effect and molecular mechanism of TQ05105, a novel small molecule inhibitor of JAK2 in myeloproliferative neoplasm","volume":"6","author":"W","year":"2022","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.ejphar.2025.178032_bib36","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1182\/blood-2023-178956","article-title":"First-in-class JAK\/ROCK inhibitor Rovadicitinib in myeloproliferative neoplasms: a single arm, multicenter, open-Label, phase I\/Ib study","volume":"142","author":"Xu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2025.178032_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000967896.90637.56","article-title":"S246: JAK\/ROCK inhibitor TQ05105 for glucocorticoid-refractory or -dependent chronic graft-versus-host disease: updated results of a phase Ib\/II study","volume":"7","author":"Zhao","year":"2023","journal-title":"HemaSphere"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925007861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T09:25:10Z","timestamp":1772789110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925007861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"alternative-id":["S0014299925007861"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178032","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-class JAK\/ROCK inhibitor, Rovadicitinib in patients with myelofibrosis who were refractory or relapsed or intolerant to Ruxolitinib: A single-arm, multicenter, open-label, phase Ib study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178032"}}